Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Amicus Therapeutics (FOLD) Shares Outstanding (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Shares Outstanding readings, the most recent being $310.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 3.95% to $310.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $310.9 million, a 3.95% increase, with the full-year FY2025 number at $310.9 million, up 3.95% from a year prior.
  • Shares Outstanding hit $310.9 million in Q4 2025 for Amicus Therapeutics, up from $308.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $310.9 million in Q4 2025 to a low of $266.5 million in Q2 2021.
  • Median Shares Outstanding over the past 5 years was $294.9 million (2023), compared with a mean of $292.9 million.
  • Biggest five-year swings in Shares Outstanding: grew 6.43% in 2021 and later increased 0.79% in 2022.
  • Amicus Therapeutics' Shares Outstanding stood at $278.9 million in 2021, then increased by 0.79% to $281.1 million in 2022, then rose by 4.44% to $293.6 million in 2023, then grew by 1.86% to $299.0 million in 2024, then rose by 3.95% to $310.9 million in 2025.
  • The last three reported values for Shares Outstanding were $310.9 million (Q4 2025), $308.5 million (Q3 2025), and $308.1 million (Q2 2025) per Business Quant data.